Trial Profile
Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Selinexor (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Nov 2023 Status changed from suspended to completed.
- 19 Apr 2023 Results assessing the molecular mechanism of synergy was evaluated in KPC mice tumors and in biopsies from patients enrolled in the Phase I portion of the trial using spatial transcriptomic and proteomic analysis and the efficacy of Sel-Gem from a Phase II study in patients with metastatic pancreatic ductal adenocarcinoma, presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 02 Feb 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.